Article Text

other Versions

PDF
Relation between changes in foveal choroidal thickness and 1-year results of ranibizumab therapy for polypoidal choroidal vasculopathy
  1. Taiichi Hikichi,
  2. Hirokuni Kitamei,
  3. Shoko Shioya,
  4. Makoto Higuchi,
  5. Takuro Matsushita,
  6. Shoko Kosaka,
  7. Reiko Matsushita,
  8. Kimitaka Takami,
  9. Hideo Ohtsuka
  1. Department of Ophthalmology, Ohtsuka Eye Hospital, Sapporo, Japan
  1. Correspondence to Dr Taiichi Hikichi, Ohtsuka Eye Hospital, Kita-16 Nishi-4, Kita-ku, Sapporo 001-0016, Japan; taiichi-hikichi{at}hokkaido.med.or.jp

Abstract

Aim To determine a correlation between changes in the subfoveal choroidal thickness and outcomes 1 year after ranibizumab therapy for polypoidal choroidal vasculopathy (PCV).

Methods We prospectively studied 89 consecutive eyes with treatment-naïve symptomatic PCV and 1 year of follow-up after treatment. The choroidal thickness was measured monthly by optical coherence tomography using enhanced-depth imaging and the correlation between the changes in the choroidal thickness and outcomes 1 year after treatment was analysed.

Results 86 eyes followed for 1 year were ultimately analysed. The mean logarithm of the minimum angle of resolution visual acuity (0.33±0.35) 1 year after the first injection significantly (p=0.001) improved compared to baseline (0.42±0.37). The mean choroidal and foveal retinal thicknesses decreased significantly (p=0.001 for both comparisons) from 271 and 347 μm to 212 and 203 μm, respectively. The amplitude of the change in the subfoveal choroidal thickness during the 1-year follow-up in eyes in which the polypoidal lesions resolved 1 year after the first injection (89±94 μm) was significantly (p=0.022) greater than in eyes in which the polypoidal lesions remained (45±109 μm).

Conclusions The subfoveal choroidal thickness decreased during ranibizumab therapy, which was associated with resolved polypoidal lesions and foveal retinal thickness, and may be associated with PCV activity.

  • Choroidal Thickness
  • Ranibizumab
  • Polypoidal Choroidal Vasculopathy

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.